U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. Creating a Public-Private Partnership to Support Development of Anti-Cancer Therapies for Ultra-Rare Tumor Indications
  1. Oncology Center of Excellence

Creating a Public-Private Partnership to Support Development of Anti-Cancer Therapies for Ultra-Rare Tumor Indications

FNIH, NCI, and FDA Public Meeting Notice

On August 24, 2023, the Foundation for the National Institutes of Health (FNIH), the National Cancer Institute (NCI), and the Oncology Center of Excellence at the Food and Drug Administration (FDA) conducted a virtual meeting to discuss plans for creating a public-private partnership (PPP) to guide and support the development of new treatments for patients with ultra-rare cancers. Many pediatric and adult ultra-rare cancers have actionable oncogenic drivers not present in more common cancers; however, there is limited economic incentive to encourage concerted and coordinated efforts to develop drugs for these ultra-rare cancers.
 
During this multi-stakeholder meeting, participants discussed options for a collaborative open-science, open-drug development process for targeted therapies for ultra-rare cancer indications. FNIH will solicit feedback and suggestions from the ultra-rare cancer community on the proposed PPP plans and gauge interest and resources available for drug development in this arena. 

Meeting Date: August 24, 2023
Meeting Time: 11:00-15:00 US Eastern Time
Meeting Format: Virtual

Watch on YouTube

Workshop Materials

If you have any questions prior to the meeting, please feel free to contact the FNIH team: Stacey Adam (sadam@fnih.org), Dana Connors (dconnors@fnih.org), and Katherine Lambertson (klambertson@foundationfornih.org).

Further Information

Back to Top